Making Cents Sense

TL;DR UnitedHealth Group (UNH) is limping through one of the toughest resets in its modern history—yet the math for a rebound to $400+ by year-end FY 2026 is straightforward: (1) 2026 Medicare Advantage (MA) repricing plus a +5.06% CMS rate tailwind, (2) OptumRx and Optum Insight grinding out steadier margins, (3) cyberattack costs fading into the rearview, and (4) a historically compressed valuation that doesn’t need to revisit old peaks to re-rate. If adjusted EPS recovers into the $24.5–$27.0 zone in 2026 and the multiple stabilizes at 16–17× , you’re looking at $404–$459 , before dividends. The road isn’t risk-free—utilization, PBM scrutiny, and DOJ/FTC probes are real—but the path is visible. CMS UnitedHealth Group CompaniesMarketCap Where We Are Now (Late 2025 Reality Check) Price & Valuation. UNH closed around $309.87 most recently. At that price, trailing P/E hovers near ~13× , well below its 3-, 5-, and 10-year averages (low-20s). On a cash yield lens, the new $2....

UnitedHealth Group, a titan in the American healthcare landscape, is undergoing a seismic transformation that has the industry buzzing and investors holding their breath. As the largest health insurer in the United States, UnitedHealth isn’t just adjusting its sails — it’s gutting the ship and rebuilding in the midst of a storm. Leadership turnover, shifting regulatory winds, strategic retreats from international waters, and a series of unfortunate and bizarre events have left the healthcare giant looking more like a crisis PR case study than a Wall Street darling. Welcome to the UnitedHealth 2025 saga: where executives resign, CEOs die under mysterious circumstances, and billions vanish in Latin America faster than you can say "Banmedica." So buckle up. We’re going deep into what the hell is going on, why it matters, and what might come next. Chapter One: The Witty Exit – No Joke Sir Andrew Witty, a name that once carried calm, bureaucratic British efficiency, resigned in Ma...